Company to showcase EsoGuard® and
EsoCheck® at the conference's Innovation
Pavilion
NEW
YORK, Oct. 8, 2024 /PRNewswire/ -- Lucid
Diagnostics Inc. (Nasdaq: LUCD) ("Lucid" or the
"Company"), a commercial-stage, cancer prevention medical
diagnostics company, and subsidiary of PAVmed Inc. (Nasdaq: PAVM),
today announced that the Company and several of its key executives
will be participating in the upcoming The MedTech Conference 2024,
the world's foremost annual medical technology event, which will be
held October 15-17, 2024, in
Toronto, Canada. The MedTech
Conference is organized by AdvaMed, the world's leading medical
technology association. Lucid and its team will be highlighted at
multiple conference venues and events.
Innovation Pavilion
Lucid has been selected to participate in the conference's
prestigious Innovation Pavilion, a dedicated area within the
MedTech Campus for device, diagnostic, and digital health companies
to showcase their cutting-edge technologies. The Lucid team, led by
Jessie Gifford, Lucid's Senior
Director of Product Development & Manufacturing, will host live
demonstrations of Lucid's EsoCheck® Esophageal Cell
Collection Device and showcase the performance of its
EsoGuard® Esophageal DNA Test, allowing conference
attendees to experience firsthand how these innovative technologies
seek to prevent esophageal cancer through widespread, early
detection of esophageal precancer in at-risk patients.
CEOs Unplugged Event
Lishan Aklog, M.D., Lucid's
Chairman and Chief Executive Officer, will be featured at one of
the conference's CEOs Unplugged events where he will be joined by
distinguished panelists, including
- Caroline Irungu, Global VP of
Medtech at Dassault Systemes;
- Jaime Wheeler, VP of Global
Clinical Affairs at Edwards Lifesciences; and
- Jean-Claude Dubacher, Chairman and Chief Executive Officer
of B. Braun of America Inc.
Dr. Aklog proudly represents Lucid and PAVmed in several key
leadership positions within the AdvaMed organization. As a member
of the Executive Committee of the AdvaMed Board of Directors, he
contributes to strategic initiatives that advance the medical
technology sector. He also serves on the AdvaMedDx Board of
Directors, which focuses on the vital interests of diagnostic
companies and as Chairman of the AdvaMed Accel Board of Directors,
which supports the growth and development of small medical
technology companies, such as Lucid.
Company Presentation
As part of the conference's Investor Forum, Shaun O'Neil, Lucid's President and Chief
Operating Officer, will deliver Lucid's Company Presentation on
Tuesday, October 15, 2024, from
3:45-3:55 PM.
"The MedTech Conference has become the world's leading annual
event for the medical technology industry and offers Lucid the
opportunity to engage with industry leaders, potential strategic
partners, and investors who are shaping the future of healthcare,"
said Dr. Aklog. "We are excited to have been selected to exhibit in
the Innovation Pavilion, where we will showcase our groundbreaking
technologies, EsoGuard and EsoCheck, and to have a strong presence
throughout the conference."
The MedTech Conference, organized by AdvaMed (the Advanced
Medical Technology Association), is the premier annual event for
the medical technology industry, with over 1,500 companies and
attendees from 45 countries expected to participate this year.
AdvaMed is the world largest medical technology association,
representing over 500 companies that produce medical devices,
diagnostic products, and health information systems. AdvaMed
advocates for patient access to safe, effective, and innovative
technologies that save and improve lives.
About Lucid Diagnostics
Lucid Diagnostics Inc. is a commercial-stage, cancer prevention
medical diagnostics company and subsidiary of PAVmed Inc. (Nasdaq:
PAVM). Lucid is focused on the millions of patients with
gastroesophageal reflux disease (GERD), also known as chronic
heartburn, who are at risk of developing esophageal precancer and
cancer. Lucid's EsoGuard® Esophageal DNA Test, performed
on samples collected in a brief, noninvasive office procedure with
its EsoCheck® Esophageal Cell Collection Device,
represent the first and only commercially available tools designed
with the goal of preventing cancer and cancer deaths through
widespread, early detection of esophageal precancer in at-risk
patients.
For more information about Lucid, please visit www.luciddx.com
and for more information about its parent company PAVmed, please
visit www.pavmed.com.
Forward-Looking Statements
This press release includes forward-looking statements that
involve risk and uncertainties. Forward-looking statements are any
statements that are not historical facts. Such forward-looking
statements, which are based upon the current beliefs and
expectations of Lucid's management, are subject to risks and
uncertainties, which could cause actual results to differ from the
forward-looking statements. Risks and uncertainties that may cause
such differences include, among other things, volatility in the
price of Lucid's common stock; general economic and market
conditions; the uncertainties inherent in research and development,
including the cost and time required to advance Lucid's products to
regulatory submission; whether regulatory authorities will be
satisfied with the design of and results from Lucid's clinical and
preclinical studies; whether and when Lucid's products are cleared
by regulatory authorities; market acceptance of Lucid's products
once cleared and commercialized; Lucid's ability to raise
additional funding as needed; and other competitive developments.
In addition, Lucid continues to monitor the COVID-19 pandemic and
the pandemic's impact on Lucid's businesses. These factors are
difficult or impossible to predict accurately and many of them are
beyond Lucid's control. In addition, new risks and uncertainties
may arise from time to time and are difficult to predict. For a
further list and description of these and other important risks and
uncertainties that may affect Lucid's future operations, see Part
I, Item 1A, "Risk Factors," in Lucid's most recent Annual Report on
Form 10-K filed with the Securities and Exchange Commission, as the
same may be updated in Part II, Item 1A, "Risk Factors" in any
Quarterly Report on Form 10-Q filed by Lucid Diagnostics after its
most recent Annual Report. Lucid disclaims any intention or
obligation to publicly update or revise any forward-looking
statement to reflect any change in its expectations or in events,
conditions, or circumstances on which those expectations may be
based, or that may affect the likelihood that actual results will
differ from those contained in the forward-looking statements.
View original content to download
multimedia:https://www.prnewswire.com/news-releases/lucid-diagnostics-to-join-global-medtech-leaders-at-the-medtech-conference-2024-302269914.html
SOURCE Lucid Diagnostics